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Abstract: As part of a national surveillance programme initiated in 2004, fungal blood isolates from
2016–2018 underwent species identification and EUCAST susceptibility testing. The epidemiology
was described and compared to data from previous years. In 2016–2018, 1454 unique isolates were
included. The fungaemia rate was 8.13/100,000 inhabitants compared to 8.64, 9.03, and 8.38 in 2004–
2007, 2008–2011, and 2012–2015, respectively. Half of the cases (52.8%) involved patients 60–79 years
old and the incidence was highest in males ≥70 years old. Candida albicans accounted for 42.1% of all
isolates and Candida glabrata for 32.1%. C. albicans was more frequent in males (p = 0.03) and C. glabrata
in females (p = 0.03). During the four periods, the proportion of C. albicans decreased (p < 0.001), and
C. glabrata increased (p < 0.001). Consequently, fluconazole susceptibility gradually decreased from
68.5% to 59.0% (p < 0.001). Acquired fluconazole resistance was found in 4.6% Candida isolates in
2016–2018. Acquired echinocandin resistance increased during the four periods 0.0%, 0.6%, 1.7% to
1.5% (p < 0.0001). Sixteen echinocandin-resistant isolates from 2016–2018 harboured well-known FKS
resistance-mutations and one echinocandin-resistant C. albicans had an FKS mutation outside the
hotspot (P1354P/S) of unknown importance. In C. glabrata specifically, echinocandin resistance was
detected in 12/460 (2.6%) in 2016–2018 whereas multidrug-class resistance was rare (1/460 isolates
(0.2%)). Since the increase in incidence during 2004–2011, the incidence has stabilised. In contrast,
the species distribution has changed gradually over the 15 years, with increased C. glabrata at the
expense of C. albicans. The consequent decreased fluconazole susceptibility and the emergence of
acquired echinocandin resistance complicates the management of fungaemia and calls for antifungal
drug development.
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1. Introduction
Candidaemia is the most common manifestation of fungaemia and of invasive can-
didiasis [1]. The overall 30-day mortality rate was 43% and even higher (54%) in the
intensive care unit (ICU) in a nationwide study in Denmark in 2010–2011 [2]. Host factors
include multimorbidity and gastrointestinal disease [2]. Main risk factors are prior ab-
dominal/complicated surgery, antibiotic exposure, an indwelling central venous catheter,
and Candida colonisation [2]. The recommended first-line treatment of candidaemia is
echinocandin [3–5].
The Danish candidaemia surveillance has existed since 2003 [6,7] and has been nation-
wide since 2004 [8–10]. The highest annual incidence in Denmark was 10.05/100,000 in-
habitants in 2011 [9]. During the surveillance period echinocandin resistance has emerged
and fluconazole non-susceptibility increased [10]. Echinocandin resistance has emerged
particularly in C. glabrata. The target enzyme for the echinocandins, the β-(1,3)-D-glucan
synthase, is encoded by the FKS genes [11,12]. Mutations in specific “hotspot” regions
of FKS1 for all Candida species as well as FKS2 for C. glabrata lead to MIC elevation and
reduce the sensitivity of the enzyme up to several thousandfold [13]. The position of the
mutation, the specific amino acid alteration, and the species in which it is inserted all affect
the level of resistance [11]. Therefore, FKS sequencing is highly informative and essential
for interpretation, particularly of MICs close to the echinocandin breakpoint.
Denmark has the highest fungaemia incidence among the Nordic countries [14–18].
Suggested causes have been a higher antibacterial drug use and a higher prevalence
of haematological malignancy [19]. The impact of antibiotic use was supported by a
Danish study on ICU patients, which found that exposure to ciprofloxacin-containing
antibiotics increased the risk of invasive Candida infections [20]. In contrast, the importance
of differences in prevalence of underlying haematologic malignancy was not supported, as
only a minority of Danish candidaemia patients had underlying haematological disease
(9%) [2].
Denmark has also experienced a larger shift in species proportion from Candida albicans
to Candida glabrata than the other Nordic countries and has had the highest consumption
of antifungal drugs in both the primary and hospital sector [19]. Prior antifungal use has
been shown to lead to a higher proportion of candidaemia with non-C. albicans species,
especially C. glabrata following azole and C. parapsilosis following echinocandin exposure [1].
Azole antifungal agents are recommended as prophylaxis for certain patient groups in
Denmark depending on their underlying disease and risk factors—especially in the ICU, in
haematological patients, in low-birth-weight neonates, and in lung and liver transplant
recipients [3].
Due to the changing epidemiology, the active nationwide surveillance programme
has continued. Knowledge of the local epidemiology is important for timely revision of
guidelines for initial antifungal therapy and informative with respect to whether changes in
antifungal stewardship approaches, infection control, or prophylaxis strategies are needed.
We report the most recent national data on the epidemiology of fungaemia including
antifungal susceptibility over a 15-year perspective.
2. Materials and Methods
2.1. Isolates, Episode Definition, and Blood-Culture Systems
Fungal blood isolates were referred to the National Reference Mycology Laboratory
at Statens Serum Institut for species verification and susceptibility testing from the ten
Danish clinical microbiological departments in the years 2016 to 2018. Thirteen isolates
(0.9%) were not referred for confirmatory identification and susceptibility testing, but are
included in the analysis according to the species identification performed locally. These
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included: C. glabrata n = 6, C. albicans n = 4, C. krusei n = 1, Candida parapsilosis n = 1,
and Candida dubliniensis n = 1. Confirmatory species identification was performed based
upon morphology and Matrix-assisted laser desorption/ionisation time-of-flight mass
spectrometry (Bruker, Bremen, Germany) [9] with the online available spectrum database
MSI [21] or DNA sequencing as previously described when needed [10].
Isolates were considered unique despite originating from the same patient if either (a)
belonging to a different species, (b) having a different susceptibility pattern, or (c) obtained
more than 21 days apart. Non-unique isolates were excluded. An episode was defined as
polyfungal when more than one species was isolated in blood cultures obtained the same
day. The numbers of episodes were centre-based, in accordance with previous Danish
candidaemia publications [7,9,10,22]. The incidences are defined as number of episodes
relative to the number of inhabitants, discharges, or bed days.
Most departments served several hospitals. Four centres used BacT/ALERT (bioMérieux,
Marcy l’Etoile, France), one centre used BACTEC (Becton Dickinson, Franklin Lakes, NJ,
USA), and the remaining five either changed systems during the study period or used both
systems concomitantly (Supplementary Table S1).
2.2. Susceptibility Testing and FKS Gene Sequence Analysis
Susceptibility testing was done prospectively for ≥98.8% of the isolates according
to EUCAST E.Def 7.3 [23]. Stock solutions (5000 mg/L in dimethyl sulfoxide (DMSO;
Sigma-Aldrich, Brøndby, Denmark) were used of the following compounds: fluconazole,
voriconazole and amphotericin B (Sigma- Aldrich), anidulafungin (Pfizer A/S, Ballerup,
Denmark), and micafungin (Astellas Pharma Inc., Tokyo, Japan; and Molcan Corporation,
Toronto, Canada from 15 May 2018). C. parapsilosis ATCC 22019, or C. krusei ATCC 6258,
or both were included as quality controls. The final test concentration ranges varied over
the years, but the following concentrations were included throughout: amphotericin B
0.016–4 mg/L, anidulafungin 0.008–1 mg/L (C. dubliniensis: 0.004–1 mg/L), micafungin
0.008–1 mg/L, fluconazole 0.125–16 mg/L, and voriconazole 0.03–4 mg/L. Susceptibility
classification was performed adopting the current EUCAST clinical breakpoints v. 10.0 [24].
For drug-species combinations without breakpoints, MICs were interpreted as follows. For
amphotericin B, the non-species-specific susceptibility breakpoint of 1 mg/L was used for
all species, except C. lusitaniae (which is regarded as intrinsically resistant regardless of the
MIC due to a high mutation rate and lower amphotericin B cidality [25]). For fluconazole,
the EUCAST non-species-specific breakpoints were used (S: ≤2 and R: >4 mg/L) for all
Candida spp. For echinocandins against C. dubliniensis specifically, single-centre 99% wild-
type upper limits (WT-UL99) were determined using the ECOFF finder program v. 2.1 [26]
and adopted as susceptibility breakpoints (anidulafungin: ≤0.03 mg/L and micafungin:
≤0.06 mg/L). Finally, established EUCAST ECOFFs were used to determine the propor-
tion of non-wildtype isolates according to the European Committee on Antimicrobial
Susceptibility Testing [27].
FKS sequencing was performed as previously described for Candida isolates with an
elevated echinocandin MIC [10]. In case of discordant susceptibility classification for anidu-
lafungin and micafungin, the isolate was deemed resistant if FKS sequencing confirmed
a known hotspot alteration. Acquired echinocandin resistance rates were determined for
C. albicans, C. dubliniensis, C. glabrata, C. krusei, Candida tropicalis, and Candida kefyr, and
compared with data from the previous years [10].
2.3. Population Data
Annual Danish population data from the first quartile was obtained from dst.dk
accessed on 25 May 2021. The total numbers of discharges and bed days among somatic
admissions were obtained and accessed on 19 December 2019 from www.esundhed.dk.
Furthermore, the microbiologists at the clinical microbiological departments provided data
separately from their own centre. Numbers of selected abdominal surgical procedures were
available at www.esundhed.dk accessed on 25 May 2021, from the period 2005 to 2018.
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In order to use Poisson regression analysis and compare numbers of episodes in
patient groups relative to the population number per year, patients count individually per
year and according to patient ID in the current study period.
2.4. Consumption of Antifungal Compounds
The antifungal consumption for Denmark was retrieved for primary health care sector
and hospital from the website www.medstat.dk, obtained and accessed on 8 July 2020.
Global antifungal use for Norway, Sweden, and Finland (DDD/1000 inhabitants/year)
was acquired from Grossistbasert legemiddelstatistikk, Folkehelseinstituttet or in English:
Norwegian Drug Wholesales Statistics, Norwegian Institute of Public Health—www.fhi.no,
obtained and accessed on 21 August 2020; www.socialstyrelsen.se, obtained and accessed
on 15 August 2017; and www.firmea.fi, obtained and accessed on 6 September 2020,
respectively. Data on antifungal consumption in Sweden were not available for 2017 and
2018, thus the comparison is made only for Denmark, Norway, and Finland for these years.
2.5. Statistics
The χ2-test was used when comparing isolate proportions in groups, and Fischer’s
exact test was used when the expected counts were <5. The χ2-test for a trend was used
when comparing isolate proportions in a four-period time interval or more than two age
groups, using GraphPad Prism v. 8.3.0. (San Diego, CA, USA). A negative binominal
dispersion was used when comparing numbers of episodes relative to the number of
bed days in the four periods as well as numbers of episodes relative to the numbers of
inhabitants for the period 2011 to 2018 using IBM SPSS Statistics v. 26 (Armonk, New York,
NY, USA). A Poisson regression analysis was used for numbers of episodes in gender and
age groups using IBM SPSS Statistics v. 26.
The study was approved by Compliance at Statens Serum Institut (journal number:
21/00993).
3. Results
A total of 1454 unique blood isolates from 1402 unique episodes in 1311 patients were
collected in the years 2016 to 2018 (Table 1). Half of the candidaemia cases (52.8%) involved
patients 60–79 years old (Supplementary Table S2). Most episodes occurred in males (60%)
(Table 1). The age and gender group that contained the highest number of isolates (21.1%)
was males 70–79 years old (Figure 1).




Figure 1. Number of isolates according to age and gender in 2016 to 2018. 
Table 1. Population and patient demographics, episode rates, and species distribution. 
 2016 2017 2018 2016–2018 
Number of isolates 453 482 519 1454 
Number of episodes 436 464 502 1402 
Number of patients 409 432 470 1311 
Median age (range) 70 (0–96) 71 (0–102) 69.5 (0–96) 70 (0–102) 










Population  5,707,251 5,748,768 5,781,190 5,745,736.3 a 
Incidences of episodes      
Per 100,000 inhabitants 7.64 8.07 8.68 8.13 
Per 1000 discharges 0.31 0.33 0.37 0.34 
Per 10,000 bed days 1.02 1.10 1.21 1.11 
Number of isolates  
(% of total) 
    
C. albicans 195 (43%) 190 (39.4%) 227 (43.7%) 612 (42.1%) 
C. glabrata 146 (32.2%) 167 (34.6%) 154 (29.7%) 467 (32.1%) 
C. dubliniensis 17 (3.8%) 27 (5.6%) 29 (5.6%) 73 (5.0%) 
C. tropicalis 27 (6.0%) 26 (5.4%) 22 (4.2%) 75 (5.2%) 
C. parapsilosis 16 (3.5%) 20 (4.1%) 26 (5.0%) 62 (4.3%) 
C. krusei 25 (5.5%) 24 (5.0%) 24 (4.6%) 73 (5.0%) 
Candida spp. b 16 (3.5%) 21 (4.4%) 28 (5.4%) 65 (4.5%) 
Other fungi c 11 (2.4%) 7 (1.5%) 9 (1.7%) 27 (1.9%) 
a mean population during the three years. b Candida spp.: C. lusitanae (n = 22), C. guilliermondii (9), C. kefyr (8), C. orthopsilosis 
(5), C. metapsilosis (3), C. pelliculosa (3), C. species (3), C. fermentati (2), C. inconspicua (2), C. norvegensis (2), C. utilis (2), C. 
nivariensis (1), C. pararugosa or Wickerhamiella pararugosa (1), Lodderomyces elongisporus (1), C. eremophila (Pichia kluyveri) (1). 
c Other fungi: Cryptococcus neoformans (9), Saccharomyces cerevisiae (7), Magnusiomyces capitatus (formerly known as Ge-
otrichum capitatum) (4), Saccharomyces telluris (1), Cryptococcus albidus (1), Rhodotorula mucilaginosa (1), Fusarium dimerum (1), 
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Table 1. Population and patient demographics, episode rates, and species distribution.
2016 2017 2018 2016–2018
Number of isolates 453 482 519 1454
Number of episodes 436 464 502 1402
Number of patients 409 432 470 1311
Median age (range) 70 (0–96) 71 (0–102) 69.5 (0–96) 70 (0–102)










Population 5,707,251 5,748,768 5,781,190 5,745,736.3 a
Incidences of episodes
Per 100,000 inhabitants 7.64 8.07 8.68 8.13
Per 1000 discharges 0.31 0.33 0.37 0.34
Per 10,000 bed days 1.02 1.10 1.21 1.11
Number of isolates
(% of total)
C. albicans 195 (43%) 190 (39.4%) 227 (43.7%) 612 (42.1%)
C. glabrata 146 (32.2%) 167 (34.6%) 154 (29.7%) 467 (32.1%)
C. dubliniensis 17 (3.8%) 27 (5.6%) 29 (5.6%) 73 (5.0%)
C. tropicalis 27 (6.0%) 26 (5.4%) 22 (4.2%) 75 (5.2%)
C. parapsilosis 16 (3.5%) 20 (4.1%) 26 (5.0%) 62 (4.3%)
C. krusei 25 (5.5%) 24 (5.0%) 24 (4.6%) 73 (5.0%)
Candida spp. b 16 (3.5%) 21 (4.4%) 28 (5.4%) 65 (4.5%)
Other fungi c 11 (2.4%) 7 (1.5%) 9 (1.7%) 27 (1.9%)
a mean population during the three years. b Candida spp.: C. lusitanae (n = 22), C. guilliermondii (9), C. kefyr (8), C. orthopsilosis (5),
C. metapsilosis (3), C. pelliculosa (3), C. species (3), C. fermentati (2), C. inconspicua (2), C. norvegensis (2), C. utilis (2), C. nivariensis
(1), C. pararugosa or Wickerhamiella pararugosa (1), Lodderomyces elongisporus (1), C. eremophila (Pichia kluyveri) (1). c Other fungi:
Cryptococcus neoformans (9), Saccharomyces cerevisiae (7), Magnusiomyces capitatus (formerly known as Geotrichum capitatum)
(4), Saccharomyces telluris (1), Cryptococcus albidus (1), Rhodotorula mucilaginosa (1), Fusarium dimerum (1), Fusarium solani (1),
Barnettozyma salicaria (formerly known as Pichia salicaria) (1), and mould not further identified due to insufficient growth (1).
3.1. Incidence
The incidence was 8.13/100,000 inhabitants in 2016–2018 compared to 8.64, 9.03 and
8.38 per 100,000 inhabitants in the time periods 2004–2007, 2008–2011, and 2012–2015,
respectively (Table 1, Table 2, and Figure 2). The incidence did not decrease significantly
from the peak in 2011 to 2018 (p = 0.08). The numbers of episodes relative to the numbers
of bed days increased significantly in the four periods (p < 0.001). The highest incidences
were observed at the extremes of age (Figure 3). Gender-specific incidences were different:
there were 9.73/100,000 male inhabitants and 6.56/100,000 female inhabitants in 2016–2018,
with a male/female incidence rate ratio (IRR) of 1.666 (95% CI: 1.655–1.668).
Table 2. Data in a four-period perspective.
2004–2007 2008–2011 2012–2015 2016–2018
Incidences of episodes
per 100,000 inhabitants 8.64 9.03 8.38 8.13
per 1000 discharges 0.39 0.38 0.34 0.34
per 10,000 bed days 0.90 1.03 1.06 1.11
Elderly population (≥70 years) 573,697 600,248 661,414 761,795
Numbers of selected surgical procedures
(mean/year) 134,468 152,086 195,329 238,072
Numbers of admission to the intensive care unit
(mean/year) 11,193 11,345 12,472 12,596
Susceptibility
Echinocandin acquired resistance rate (%) 0 (0/1294) 0.6 (10/1581) 1.7 (29/1754) 1.5 (19/1295)
Fluconazole susceptibility rate (%) 68.5 (972/1420) 65.2 (1137/1745) 60.6 (1147/1892) 59.0 (848/1438)
The number for the elderly population ≥70 years is the mean number per year in the stated period. Numbers of selected surgical procedures
and bed days were available at www.esundhed.dk accessed on 25 May 2021. Operations on the digestive tract and spleen, punctures and
punctual biopsies/smaller surgeries, and endoscopies were chosen. Numbers stated as “<5” at www.esundhed.dk accessed on 25 May 2021
were not included in the calculations. Numbers of admissions to the intensive care unit were provided by RKKP (Regionernes Kliniske
Kvalitetsudviklingsprogram) from the Danish Intensive Database.
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The incidence rate was significantly higher in the older age groups for both males
(80–89 and ≥90 years) and for females (80–89 years) compared to all other age groups
(Figure 3, Supplementary Table S3).
3.2. Species Distribution
C. albicans (42.1%) and C. glabrata (32.1%) were the two dominant species in 2016–2018.
C. albicans accounted for less than 40% in 2017 (Table 1, Figure 2). C. tropicalis, C. krusei,
C. dubliniensis, and C. parapsilosis each accounted for ≤5.2%; other Candida species 4.5%;
and isolates (n = 27) other than Candida accounted for 1.9% (Table 1, Figure 2). Polyfungal
episodes (n = 52) accounted for 3.7% of the episodes and half of these involved C. albicans
and C. glabrata (n = 27, 1.9% of all). Notable differences in the epidemiology were observed
between the specific centres (Supplementary Table S1). Comparing the seven centres
serving university (± district) hospitals that all had >100 (range 149–258) blood-culture
isolates, the incidence varied three-fold (5.62–14.6/100,000 inhabitants and 0.59–1.94/10,000
bed days), and the C. albicans and C. glabrata proportions varied 34.4–48.4% and 24.7–38.0%,
respectively.
During 2004–2018 C. albicans decreased (64.4% to 43.7%) and C. glabrata increased
(16.5% to 29.7%) [22], (both p < 0.0001 compared with 2004–2007, 2008–2011, 2012 –2015,
and 2016–2018). Moreover, C. dubliniensis and other Candida species increased (p < 0.001
and p = 0.004, respectively), whereas the proportions of C. krusei, C. parapsilosis, and C.
tropicalis remained stable (Figure 2).
3.3. Species and Gender
In 2016–2018 C. albicans was more common in males than females (44.4% and 38.8%,
p = 0.03), and C. glabrata was more common in females than in males (35.3% and 29.9%,
p = 0.03).
3.4. Species and Age
The proportion of C. glabrata isolates increased with increasing age group (p < 0.001).
Of note, C. parapsilosis was not detected among patients <1 years, and only a single C.
parapsilosis has been found in this age group (2.4%) since 2012 as compared to 10 (16.9%)
during 2004–2011 (p= 0.03) (Figure 4). The age-specific species distribution also varied
among the centres. The referral hospital Rigshospitalet had the lowest proportion of C.
glabrata and the highest proportion of patients with candidaemia in the age group below
50 years. Details of blood-culture systems and centre-specific incidences are presented in
Supplementary Table S1.
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Thirteen isolates were not referred, and two isolates were not susceptibility tested, as fur-
ther detailed in the methods section. 
Acquired echinocandin resistance was detected in 19 isolates: 12/460 C. glabrata iso-
lates, 5/72 C. krusei isolates, 1/72 C. dubliniensis, 1/608 C. albicans, 0/75 C. tropicalis, and 0/8 
C. kefyr. The acquired echinocandin resistance rate among species that are normally sus-
ceptible but in which acquired resistance has previously been reported was 1.5% (19/1295) 
in 2016–2018, and increased in a four-period perspective (p <0.001). Of the resistant iso-
lates, 16 harboured FKS hot-spot alterations. Six isolates harboured FKS alterations out-
side the hot-spot regions (Table 4). The echinocandin resistance rate in C. glabrata, specif-
ically, was 2.6% (12/460). Of those 8.3% (1/12) was also fluconazole resistant, but none 
displayed resistance to amphotericin B. Susceptibility to amphotericin B was overall 
99.9%. 
Acquired fluconazole resistance accounted for 4.6% (59/1276) among the most com-
mon species that are normally either S or I to fluconazole. In detail, acquired fluconazole 
resistance was detected in 0.5% (3/608) C. albicans, 4.2% (3/72) C. dubliniensis, 10.7% 
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3.5. Susceptibility
MICs for the 1439 isolates referred for susceptibility testing are shown in Table 3.
Thirteen isolates were not referred, and two isolates were not susceptibility tested, as
further detailed in the methods section.
Acquired echinocandin resistance was detected in 19 isolates: 12/460 C. glabrata iso-
lates, 5/72 C. krusei isolates, 1/72 C. dubliniensis, 1/608 C. albicans, 0/75 C. tropicalis, and 0/8
C. kefyr. The acquired echinocandin resistance rate among species that are normally suscep-
tible but in which acquired resistance has previously been reported was 1.5% (19/1295) in
2016–2018, and increased in a four-period perspective (p <0.001). Of the resistant isolates,
16 harboured FKS hot-spot alterations. Six isolates harboured FKS alterations outside the
hot-spot regions (Table 4). The echinocandin resistance rate in C. glabrata, specifically, was
2.6% (12/460). Of those 8.3% (1/12) was also fluconazole resistant, but none displayed
resistance to amphotericin B. Susceptibility to amphotericin B was overall 99.9%.
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Table 3. Susceptibility table for fungal blood isolates in 2016 to 2018.
Species and
Compound
Number of Isolates with the Given MIC (mg/L) S R Non-Wildtype













C. albicans (n = 608)
Amphotericin B 19 186 354 49 608 100% 0 0 0 0
Anidulafungin 577 29 2 608 100% 0 0 0 0
Micafungin 362 228 17 1 607 99.8% 1 0.2% 18 3.0%
Fluconazole 275 303 22 1 1 3 3 602 99.0% 3 0.5% 8 1.3%
Voriconazole 602 2 1 1 2 604 99.3% 4 0.7% 6 1.0%
C. dubliniensis (n = 72)
Amphotericin B 6 28 28 10 72 100% 0 0 0 0
Anidulafungin 37 * 29 5 1 71 98.6% 1 1.4% ND ND
Micafungin 11 31 27 2 1 71 98.6% 1 1.4% ND ND
Fluconazole 33 28 7 1 1 2 68 94.4% 3 4.2% 4 5.6%
Voriconazole 69 2 1 69 95.8% 0 0 3 4.2%
C. glabrata (n = 460)
Amphotericin B 3 11 58 239 148 1 460 100% 0 0 0 0
Anidulafungin 10 167 212 65 1 2 1 2 454 98.7% 6 1.3% 6 1.3%
Micafungin 90 247 113 5 2 2 1 450 97.8% 10 2.2% 10 2.2%
Fluconazole 2 10 142 223 28 6 49 0 0 49 10.7% 49 10.6%
Voriconazole 53 252 92 9 5 11 26 10 2 IE IE IE IE 38 8.3%
C. krusei (n = 72)
Amphotericin B 1 47 24 72 100% 0 0 0 0
Anidulafungin 16 38 15 2 1 69 95.8% 3 4.2% 3 4.2%
Micafungin 7 54 7 3 1 IE IE IE IE 4 5.6%
Fluconazole 2 16 54 0 0 72 100% ND ND
Voriconazole 16 36 13 5 1 1 IE IE IE IE 2 2.8%
C. parapsilosis sensu
stricto (n = 61)
Amphotericin B 1 18 41 1 61 100% 0 0 0 0
Anidulafungin 1 20 21 15 4 61 100% 0 0 0 0
Micafungin 1 2 27 30 1 60 98.4% 1 1.6% 1 1.6%
Fluconazole 1 34 20 5 1 60 98.% 1 1.6% 1 1.6%
Voriconazole 58 2 1 60 98.4% 1 1.6% 1 1.6%




Number of Isolates with the Given MIC (mg/L) S R Non-Wildtype













C. tropicalis (n = 75)
Amphotericin B 4 36 34 1 75 1 0 0 0 0
Anidulafungin 13 43 19 75 1 0 0 0 0
Micafungin 6 12 53 4 IE IE IE IE 0 0
Fluconazole 4 27 25 13 1 2 1 1 1 70 93.3% 3 4.0% 6 8.0%
Voriconazole 66 3 2 1 1 2 69 92.0% 4 5.3% 6 8.0%
C. species (n = 65)
Amphotericin B 1 3 17 25 13 6 43 100 0 0 ND ND
Anidulafungin 6 7 17 10 6 8 3 7 1 ND ND ND ND ND ND
Micafungin 4 10 23 6 10 12 ND ND ND ND ND ND
Fluconazole 1 10 16 6 9 10 2 5 6 42 64.6% 13 20% ND ND
Voriconazole 38 5 13 5 2 2 ND ND ND ND ND ND
Other fungi
Amphotericin B
(n = 26) 2 4 9 4 6 1 25 96.2% 1 3.8% ND ND
Anidulafungin
(n = 20) 2 1 3 1 2 1 1 2 7 ND ND ND ND ND ND
Micafungin
(n = 20) 3 3 2 2 10 ND ND ND ND ND ND
Fluconazole
(n = 25) 2 4 4 5 7 3 6 24.0% 15 60.0% ND ND
Voriconazole




(n = 1439) 6 32 63 280 682 336 39 1 1416 99.9% 1 0.001% ND ND
Anidulafungin
(n = 1433) 643 293 294 93 10 14 25 31 17 6 7 ND ND ND ND ND ND
Micafungin
(n = 1433) 469 522 220 45 65 20 19 30 31 1 11 ND ND ND ND ND ND
Fluconazole
(n = 1438) 313 369 106 52 162 243 38 36 119 848 59.0% 159 ** 11.1% ND ND
Voriconazole
(n = 1438) 891 271 127 57 23 20 30 10 8 1 ND ND ND ND ND ND
The abbreviation n indicates the number of isolates that were tested and had an MIC value; IE: Insufficient evidence; ND: not determined. Non-WT MICs are in bold and resistant underlined. MIC values outside
the tested range are marked in grey. For other fungi, numbers of isolates tested for amphotericin B (n = 26), for anidualfungin and micafungin (n = 20), for fluconazole (n = 25), for voriconazole (n = 25). * Four
isolates with MIC ≤0.004 mg/L and 33 isolates with MIC 0.008 mg/L. ** The stated number of 159 resistant isolates for fluconazole under ‘Overall’ is based on the individual-species-specific breakpoints. None of
the tested C. parapsilosis isolates had an MIC value stated “>1” for anidulafungin or micafungin. Over time, several concentration ranges were used. Only uniform ranges are included and shown in the table. Not
all isolates were tested for all antifungal agents if known to be intrinsically resistant.
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Table 4. Identified FKS amino acid (AA) alterations. Unless stated otherwise, the detected alterations are known to be
associated with echinocandin resistance.
Species (n) Echinocandin Resistant (n) FKS Alteration Hotspot (HS) Location
Isolates with hotspot
alterations
C. glabrata (1) Yes F625S Fks1
C. glabrata (2) Yes L630Q and S663F Fks1and Fks2, respectively
C. glabrata (3) Yes F659S Fks2
C. glabrata (1) Yes F659del Fks2
C. glabrata (1) Yes L662W Fks2
C. glabrata (3) Yes S663F Fks2
C. glabrata (1) Yes S663P Fks2
C. krusei (2) Yes S659S/F Fks1
C. krusei (1) Yes S659F Fks1
C. dubliniensis (1) Yes S645P Fks1
Isolates with alterations
outside the hotspots
C. krusei (4) Yes (2) No (2) L701M * Fks1; 38 AA after HS1
C. albicans (1) Yes P1354P/S ** Fks1; 3 AA before HS2
C. lusitaniae (1) No (H657Y/L1243F/ I1283V) ** Fks 1; 15 AA after HS1; 105 AAbefore HS2 and 65 AA before HS2
* L701M is located 38 AA after hotspot 1 and is not associated with echinocandin resistance. ** Unknown association to echinocan-
din resistance.
Acquired fluconazole resistance accounted for 4.6% (59/1276) among the most com-
mon species that are normally either S or I to fluconazole. In detail, acquired fluconazole
resistance was detected in 0.5% (3/608) C. albicans, 4.2% (3/72) C. dubliniensis, 10.7%
(49/460) C. glabrata, 1.6% (1/61) C. parapsilosis, and 4.0% (3/75) C. tropicalis. Combined
fluconazole and echinocandin resistance was found in one C. albicans, one C. glabrata, and
five C. krusei. Voriconazole resistance/non-wild-type phenotype was detected in 3.7%
(47/1276) of the same most common species including 0.7% (4/608) C. albicans, 0.0% (0/72)
C. dubliniensis, 8.3% (38/460) C. glabrata, 5.3% (4/75) C. tropicalis, and 1.6% (1/61) C. parap-
silosis. The proportion of fluconazole-susceptible isolates (at standard dosing) decreased to
59.0% (848/1438) in a four-period perspective from 68.5% (972/1420), 65.2% (1137/1745),
and 60.6% (1147/1892) in 2004–2007, 2008–2011, and 2012–2015, respectively (p < 0.001,
Table 2).
3.6. Antifungal Consumption
The consumption of the antifungal agents amphotericin B, fluconazole, voricona-
zole, and posaconazole in Denmark peaked in the years 2012 to 2014. The consumption
of echinocandins has increased in Danish hospitals since 2004 and was highest in 2018
(3.3 DDDs/1000 inhabitants/year) (Figure 5 and Supplementary Figure S1). The total con-
sumption of fluconazole was highest in Denmark during 2012–2015 and decreased during
the current three-year study period to 172, 160, and 155 DDDs/1000 inhabitant/year, respec-
tively (Figure 5). During 2016–2018, 71% (1,988,000/2,803,000 DDD) of the total fluconazole
use was prescribed in the primary healthcare sector, including 74% (1,462,000/1,978,000
DDDs) prescribed in women.
From a Nordic perspective, the consumption of echinocandins was comparable to that
in the other Nordic countries. The consumption of fluconazole and posaconazole remained
notably larger in Denmark than in the other Nordic countries, and the consumption
of voriconazole and itraconazole was larger in Denmark than in Sweden and Norway
(Figure 5 and Supplementary Figure S1).
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was the main cause of the observed decrease in overall fluconazole susceptibility, yet ac-
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4. Discussion
We previously reported an increase in incidence up until 2011 and a slight decrease in
2012–2015 [10] but this trend did not seem to continue during 2016–2018. In contrast, the
incidence appears to have stabilised. Consequently, Denmark remaine hi incidenc
country from both Nordic and global perspec ives, with an incidence similar to the one
found n the CDC’s Emerging Infections Program US [14–18,28]. The species distribu
tio , however, c ntinued t shift towards a higher proport on of C. glabrata and a l wer
prop rtion of C. albicans (even below 40% in 2017). A C. albicans proportion below 40%
has been reported the US and South America [28–32], but no other Nordic country
has reported a C. albicans proportion below 50% [14,16,17,33]. This change in specie
distribution was the main cause of the observed decrease i overall fluconaz le susceptibil-
ity, yet cquired fluconazole and voriconazole resistances were fou d in 4.6% and 3.7%,
respectively, of the normally susceptible common Candida spp. isolates. The echinocan-
din resistance rate increased in a four-period perspective (where also the echinocandin
use increased), but remained stable during 2012–2018 and less common than acquired
resistance to fluconazole [10]. C. glabrata was confirmed as the species with the highest
rates of acquired echinocandin, fluconazole, and voriconazole resistance as also found
elsewhere [14,28,34]. Of note, no cases involving C. auris were detected in Denmark during
the observation period.
Candidaemia remained most frequent in males in accordance with previous find-
ings globally [2,9,10,14–16,33,35–42]. The median age (70 years) was slightly higher but
nevertheless in accordance with previous studies in Denmark, other Nordic countries
(64–69 years) and elsewhere (all above 60 years) [10,14,16,31,33,35,37–39,42]. The incidence
was highest among males in the age group ≥90 years, and thus later in life than previ-
ously [10]. Since the surveillance programme was initiated, life expectancy has increased
by 3.6 and 2.7 years for Danish males and females, respectively, which may be part of the
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explanation for the increase in median age (life expectancy—Statistics Denmark). Moreover,
an increasing number of surgical procedures and a minor increase in number of admissions
to the ICU in the elderly age groups (www.esundhed.dk/Registre accessed on 31 March
2021 and Regionernes Kliniske Kvalitetsudviklingsprogram from the Danish Intensive
Database provided 8 June 2021, respectively) suggest that more intensive management
strategies are currently offered to the elderly population.
The proportion of C. glabrata isolates increased over time, with age, and was still most
common in females [10]. Underlying drivers may be the growing elderly population and
a high azole use in Denmark, which remained higher than in the other Nordic countries,
and which in the primary health care sector is three times higher in females than in
males. C. parapsilosis was not detected in children of less than one year of age during
the current 3-year surveillance, and number of isolates was found to be significantly
less common in comparing the periods 2012–2018 with 2004–2011. This was somewhat
surprising as C. parapsilosis historically has been the second most common species in
this age group in Denmark and elsewhere [6,9,22,43,44]. A recent European paediatric
study found geographical differences in incidences of C. parapsilosis with the highest
incidence in Southern Europe [44]. It is unknown whether these differences over time and
between countries are potentially related to differences in infection control practices, use of
prophylaxis, or composition of the normal colonising flora.
This study has strengths and limitations. The major strength is that it is population
based, nationwide, and includes 15 years of continued surveillance. A limitation is the
lack of clinical data and patient-specific antifungal medication. Moreover, differences
over time and among centres in blood-culture practices (blood-culture system and sample
volume) and antifungal prophylaxis may impact blood-culture sensitivity overall and for
the individual species differentially [8]. Another potential caveat is that patients’ episodes
are counted twice when transferred between centres and when blood culture is positive
at both sites, in order to allow centre-specific incidence comparisons of the candidaemia
burden. However, since the initiation of the nationwide surveillance, the number of
clinical microbiological departments have been reduced—potentially leading to fewer
transfers between centres and thus fewer cases being counted twice. Moreover, the number
of transfer cases was limited (19 (1.4%) episodes), resulting in a corrected nationwide
incidence of 8.02 rather than 8.13/100,000 inhabitants if transferred cases were omitted, a
difference that does not affect the overall findings and conclusions of the study.
In conclusion, we found a stable incidence of fungaemia since the peak in 2011 with
a continued shift in species proportion towards C. glabrata, a decreasing overall azole
susceptibility rate and increase in acquired echinocandin and azole resistance, especially
in C. glabrata. This leads to challenges in management of candidaemia since echinocan-
din treatment in some cases is inappropriate and de-escalation to fluconazole less often
possible. This highlights the need for antifungal stewardship and new antifungal agents
with alternative targets. Notable differences were found in comparing the epidemiology
between the centres, illustrating the importance of following the local epidemiology.
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